Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Roswell Park Cancer Institute
DescriptionCancer vaccine comprising SVN53-67/M57-KLH, a peptide mimic targeting survivin (BIRC5), in adjuvant Montanide ISA 51
Molecular Target Survivin (BIRC5)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard IndicationBrain cancer
Indication DetailsTreat brain cancer
Regulatory Designation
PartnerMimiVax LLC

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today